| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nuclear Medicine | 33 | 2021 | 233 | 12.370 |
Why?
|
| Radiation Dosage | 29 | 2022 | 1927 | 2.780 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 22 | 2023 | 1107 | 2.600 |
Why?
|
| Radiopharmaceuticals | 35 | 2022 | 2658 | 2.430 |
Why?
|
| Radiometry | 14 | 2021 | 800 | 2.340 |
Why?
|
| Radionuclide Imaging | 23 | 2021 | 2027 | 2.130 |
Why?
|
| Tomography, Emission-Computed | 15 | 2016 | 1144 | 1.800 |
Why?
|
| Gastric Emptying | 9 | 2020 | 233 | 1.650 |
Why?
|
| Positron-Emission Tomography | 32 | 2022 | 6259 | 1.450 |
Why?
|
| Radiation Protection | 6 | 2020 | 419 | 1.170 |
Why?
|
| Phantoms, Imaging | 16 | 2023 | 2466 | 1.140 |
Why?
|
| Radioisotopes | 5 | 2015 | 499 | 1.090 |
Why?
|
| Pediatrics | 9 | 2020 | 3462 | 1.080 |
Why?
|
| Fluorodeoxyglucose F18 | 17 | 2022 | 2013 | 0.920 |
Why?
|
| Stomach | 5 | 2017 | 697 | 0.910 |
Why?
|
| Molecular Imaging | 6 | 2017 | 831 | 0.890 |
Why?
|
| Nuclear Physics | 3 | 2021 | 79 | 0.860 |
Why?
|
| Technetium Tc 99m Dimercaptosuccinic Acid | 6 | 2023 | 79 | 0.840 |
Why?
|
| Neoplasms, Radiation-Induced | 4 | 2017 | 546 | 0.820 |
Why?
|
| Societies, Medical | 7 | 2018 | 3740 | 0.790 |
Why?
|
| Nuclear Energy | 1 | 2019 | 14 | 0.740 |
Why?
|
| Technology, Radiologic | 2 | 2018 | 163 | 0.730 |
Why?
|
| Technetium Tc 99m Medronate | 5 | 2021 | 134 | 0.700 |
Why?
|
| Iodine | 1 | 2021 | 285 | 0.650 |
Why?
|
| Whole-Body Counting | 2 | 2017 | 35 | 0.640 |
Why?
|
| Organotechnetium Compounds | 4 | 2014 | 137 | 0.630 |
Why?
|
| Credentialing | 1 | 2018 | 126 | 0.620 |
Why?
|
| Archives | 1 | 2017 | 16 | 0.590 |
Why?
|
| Diagnostic Imaging | 6 | 2020 | 3507 | 0.580 |
Why?
|
| 3-Iodobenzylguanidine | 3 | 2013 | 115 | 0.580 |
Why?
|
| Fluorine Radioisotopes | 10 | 2015 | 448 | 0.560 |
Why?
|
| Relative Biological Effectiveness | 2 | 2017 | 323 | 0.560 |
Why?
|
| Practice Guidelines as Topic | 8 | 2019 | 7276 | 0.540 |
Why?
|
| Child | 59 | 2023 | 77478 | 0.530 |
Why?
|
| Radiation Injuries | 2 | 2014 | 1178 | 0.530 |
Why?
|
| Financial Management | 1 | 2017 | 160 | 0.520 |
Why?
|
| Rhodamines | 5 | 2015 | 183 | 0.510 |
Why?
|
| Imino Acids | 2 | 2014 | 19 | 0.510 |
Why?
|
| Reference Standards | 2 | 2016 | 1020 | 0.510 |
Why?
|
| Technetium Tc 99m Disofenin | 1 | 2014 | 13 | 0.510 |
Why?
|
| Monte Carlo Method | 4 | 2020 | 1254 | 0.500 |
Why?
|
| Safety | 2 | 2018 | 1185 | 0.480 |
Why?
|
| Biliary Tract | 1 | 2014 | 134 | 0.460 |
Why?
|
| Radioisotope Renography | 5 | 2022 | 62 | 0.430 |
Why?
|
| Gastrointestinal Contents | 1 | 2012 | 34 | 0.430 |
Why?
|
| Cheese | 2 | 2020 | 38 | 0.420 |
Why?
|
| Societies, Scientific | 2 | 2015 | 220 | 0.410 |
Why?
|
| Hospitals, General | 1 | 2016 | 749 | 0.410 |
Why?
|
| Gastrointestinal Transit | 1 | 2012 | 96 | 0.400 |
Why?
|
| Isotope Labeling | 4 | 2015 | 414 | 0.400 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2022 | 20086 | 0.380 |
Why?
|
| Quality Control | 5 | 2019 | 841 | 0.370 |
Why?
|
| Body Burden | 3 | 2010 | 158 | 0.350 |
Why?
|
| Technetium Tc 99m Mertiatide | 3 | 2022 | 22 | 0.350 |
Why?
|
| Europe | 4 | 2019 | 3339 | 0.350 |
Why?
|
| Image Processing, Computer-Assisted | 13 | 2018 | 8925 | 0.340 |
Why?
|
| Myocardial Perfusion Imaging | 6 | 2015 | 555 | 0.340 |
Why?
|
| Health Physics | 2 | 2021 | 23 | 0.340 |
Why?
|
| Imaging, Three-Dimensional | 6 | 2013 | 4029 | 0.330 |
Why?
|
| Humans | 121 | 2023 | 742088 | 0.320 |
Why?
|
| Thyroid Neoplasms | 2 | 2021 | 2274 | 0.310 |
Why?
|
| Germanium | 1 | 2007 | 7 | 0.300 |
Why?
|
| Infant | 25 | 2020 | 35070 | 0.300 |
Why?
|
| Guidelines as Topic | 3 | 2020 | 1402 | 0.280 |
Why?
|
| Gallium Radioisotopes | 1 | 2007 | 178 | 0.280 |
Why?
|
| Brain Neoplasms | 6 | 2018 | 8829 | 0.260 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2266 | 0.260 |
Why?
|
| Consensus | 1 | 2014 | 2935 | 0.260 |
Why?
|
| North America | 3 | 2015 | 1249 | 0.260 |
Why?
|
| Mandible | 1 | 2009 | 740 | 0.250 |
Why?
|
| Image Enhancement | 5 | 2010 | 2921 | 0.250 |
Why?
|
| Animals, Laboratory | 1 | 2004 | 51 | 0.250 |
Why?
|
| Glioma | 6 | 2022 | 3388 | 0.250 |
Why?
|
| Radiochemistry | 2 | 2015 | 56 | 0.250 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 1503 | 0.250 |
Why?
|
| Computer Simulation | 6 | 2023 | 6191 | 0.240 |
Why?
|
| Gamma Cameras | 6 | 2004 | 35 | 0.240 |
Why?
|
| Child, Preschool | 26 | 2020 | 40955 | 0.230 |
Why?
|
| Occupational Exposure | 1 | 2014 | 1794 | 0.230 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2015 | 281 | 0.230 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 12344 | 0.230 |
Why?
|
| Internship and Residency | 2 | 2021 | 5774 | 0.220 |
Why?
|
| Internationality | 2 | 2020 | 1002 | 0.220 |
Why?
|
| International Agencies | 2 | 2020 | 240 | 0.220 |
Why?
|
| Communication | 3 | 2023 | 3728 | 0.220 |
Why?
|
| Body Weight | 4 | 2019 | 4664 | 0.220 |
Why?
|
| Neuroblastoma | 3 | 2019 | 1225 | 0.220 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 7901 | 0.220 |
Why?
|
| Breast | 2 | 2002 | 1958 | 0.220 |
Why?
|
| Liver | 4 | 2014 | 7470 | 0.210 |
Why?
|
| Adolescent | 31 | 2020 | 85649 | 0.210 |
Why?
|
| Brain Stem Neoplasms | 2 | 2017 | 204 | 0.210 |
Why?
|
| Risk | 5 | 2016 | 9679 | 0.200 |
Why?
|
| Advisory Committees | 2 | 2016 | 773 | 0.200 |
Why?
|
| Physicians | 2 | 2021 | 4554 | 0.190 |
Why?
|
| Diagnostic Techniques, Digestive System | 1 | 2020 | 47 | 0.190 |
Why?
|
| Tissue Distribution | 5 | 2016 | 2335 | 0.180 |
Why?
|
| Copper Radioisotopes | 2 | 2010 | 86 | 0.180 |
Why?
|
| Technetium | 5 | 2010 | 334 | 0.180 |
Why?
|
| Kidney Diseases | 4 | 2022 | 2145 | 0.180 |
Why?
|
| Bone and Bones | 4 | 2020 | 2575 | 0.180 |
Why?
|
| History, 21st Century | 2 | 2017 | 1533 | 0.180 |
Why?
|
| Iodine Radioisotopes | 3 | 2021 | 1030 | 0.180 |
Why?
|
| Growth Plate | 1 | 2020 | 274 | 0.170 |
Why?
|
| Heart | 5 | 2015 | 4462 | 0.170 |
Why?
|
| Radiology | 2 | 2023 | 2090 | 0.160 |
Why?
|
| United States | 10 | 2021 | 69693 | 0.160 |
Why?
|
| Infant, Newborn | 12 | 2020 | 25575 | 0.160 |
Why?
|
| History, 20th Century | 2 | 2017 | 2739 | 0.150 |
Why?
|
| Radiation | 1 | 2017 | 49 | 0.150 |
Why?
|
| Kidney | 5 | 2023 | 7167 | 0.150 |
Why?
|
| Certification | 1 | 2021 | 423 | 0.150 |
Why?
|
| Female | 55 | 2022 | 379592 | 0.150 |
Why?
|
| Risk Assessment | 3 | 2020 | 23320 | 0.150 |
Why?
|
| Vesico-Ureteral Reflux | 2 | 2011 | 427 | 0.150 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 4 | 2004 | 66 | 0.140 |
Why?
|
| Radiography | 3 | 2021 | 7010 | 0.140 |
Why?
|
| Radiation Monitoring | 1 | 2017 | 97 | 0.140 |
Why?
|
| Organs at Risk | 1 | 2018 | 346 | 0.140 |
Why?
|
| Male | 49 | 2022 | 349538 | 0.140 |
Why?
|
| Lutetium | 1 | 2015 | 32 | 0.140 |
Why?
|
| Physics | 1 | 2016 | 87 | 0.130 |
Why?
|
| Neoplasms | 7 | 2018 | 21596 | 0.130 |
Why?
|
| Photons | 3 | 2018 | 587 | 0.130 |
Why?
|
| Eggs | 2 | 2020 | 184 | 0.130 |
Why?
|
| Algorithms | 7 | 2017 | 13853 | 0.120 |
Why?
|
| Biological Assay | 1 | 2017 | 652 | 0.120 |
Why?
|
| Knee Joint | 1 | 2003 | 1679 | 0.120 |
Why?
|
| Research Report | 2 | 2015 | 355 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 2 | 2010 | 1661 | 0.120 |
Why?
|
| Data Collection | 2 | 2002 | 3339 | 0.110 |
Why?
|
| Maryland | 1 | 2014 | 276 | 0.110 |
Why?
|
| Subtraction Technique | 3 | 2017 | 525 | 0.110 |
Why?
|
| Young Adult | 12 | 2020 | 56350 | 0.110 |
Why?
|
| Epilepsies, Partial | 1 | 2017 | 436 | 0.110 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2011 | 876 | 0.110 |
Why?
|
| Aniline Compounds | 3 | 2014 | 983 | 0.110 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2013 | 111 | 0.110 |
Why?
|
| Glycine | 2 | 2014 | 671 | 0.100 |
Why?
|
| Research | 1 | 2020 | 1999 | 0.100 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2003 | 1457 | 0.100 |
Why?
|
| Neurofibroma, Plexiform | 1 | 2012 | 69 | 0.100 |
Why?
|
| Radiographic Image Enhancement | 2 | 2003 | 885 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2019 | 35342 | 0.100 |
Why?
|
| Urography | 2 | 2010 | 313 | 0.100 |
Why?
|
| Peptides, Cyclic | 1 | 2013 | 401 | 0.090 |
Why?
|
| Sodium Fluoride | 2 | 2007 | 65 | 0.090 |
Why?
|
| Reference Values | 4 | 2020 | 4982 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2010 | 3328 | 0.090 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2012 | 190 | 0.090 |
Why?
|
| Integrin beta Chains | 1 | 2010 | 121 | 0.090 |
Why?
|
| Biological Transport | 4 | 2020 | 2119 | 0.090 |
Why?
|
| Egg Hypersensitivity | 1 | 2010 | 44 | 0.090 |
Why?
|
| Kidney Pelvis | 1 | 2011 | 188 | 0.090 |
Why?
|
| Canada | 1 | 2015 | 2061 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2015 | 1459 | 0.090 |
Why?
|
| Brain | 9 | 2012 | 26343 | 0.090 |
Why?
|
| Time Factors | 13 | 2018 | 40054 | 0.090 |
Why?
|
| International Cooperation | 1 | 2016 | 1421 | 0.090 |
Why?
|
| Radiation Oncology | 1 | 2015 | 554 | 0.090 |
Why?
|
| Adipocytes, Brown | 1 | 2010 | 144 | 0.090 |
Why?
|
| Mandibular Condyle | 1 | 2009 | 115 | 0.080 |
Why?
|
| Chelating Agents | 1 | 2010 | 380 | 0.080 |
Why?
|
| Ureteral Obstruction | 1 | 2011 | 293 | 0.080 |
Why?
|
| Neuroendocrine Tumors | 1 | 2015 | 594 | 0.080 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 1989 | 94 | 0.080 |
Why?
|
| Bone Neoplasms | 4 | 2010 | 2522 | 0.080 |
Why?
|
| Quinazolines | 1 | 2015 | 1355 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2016 | 2451 | 0.080 |
Why?
|
| Probability | 1 | 2014 | 2502 | 0.080 |
Why?
|
| Osteolysis | 1 | 2010 | 270 | 0.080 |
Why?
|
| Urinary Tract Infections | 2 | 2011 | 786 | 0.080 |
Why?
|
| Calibration | 2 | 2015 | 815 | 0.080 |
Why?
|
| Adult | 22 | 2021 | 213712 | 0.080 |
Why?
|
| Cross-Linking Reagents | 1 | 2010 | 694 | 0.070 |
Why?
|
| Thermoluminescent Dosimetry | 1 | 2007 | 24 | 0.070 |
Why?
|
| Breast Neoplasms | 3 | 2010 | 20774 | 0.070 |
Why?
|
| Seasons | 2 | 2010 | 1492 | 0.070 |
Why?
|
| Organizations | 1 | 2008 | 170 | 0.070 |
Why?
|
| Survival Rate | 3 | 2017 | 12773 | 0.070 |
Why?
|
| Health Surveys | 2 | 2016 | 4030 | 0.070 |
Why?
|
| Ion Channels | 1 | 2012 | 1056 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2015 | 895 | 0.070 |
Why?
|
| Retrospective Studies | 15 | 2022 | 77098 | 0.070 |
Why?
|
| Models, Structural | 4 | 1995 | 361 | 0.070 |
Why?
|
| Neurofibromatosis 1 | 1 | 2012 | 562 | 0.070 |
Why?
|
| Temperature | 2 | 2010 | 2207 | 0.070 |
Why?
|
| Cardiovascular System | 1 | 2014 | 827 | 0.070 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 1622 | 0.070 |
Why?
|
| Data Display | 2 | 2002 | 182 | 0.070 |
Why?
|
| Reproducibility of Results | 6 | 2011 | 19862 | 0.070 |
Why?
|
| Lymphoma | 1 | 2015 | 1873 | 0.070 |
Why?
|
| Hospitals, Pediatric | 1 | 2015 | 1760 | 0.070 |
Why?
|
| Hospitals | 2 | 2017 | 3937 | 0.070 |
Why?
|
| Scintillation Counting | 1 | 1986 | 38 | 0.070 |
Why?
|
| Genes, p53 | 1 | 2008 | 755 | 0.070 |
Why?
|
| Sensitivity and Specificity | 7 | 2011 | 14720 | 0.070 |
Why?
|
| Receptors, Notch | 1 | 2010 | 739 | 0.070 |
Why?
|
| Rats | 6 | 2015 | 24265 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2012 | 2940 | 0.060 |
Why?
|
| Osteoblasts | 1 | 2010 | 1163 | 0.060 |
Why?
|
| Retinoblastoma Protein | 1 | 2008 | 701 | 0.060 |
Why?
|
| Radiotherapy | 1 | 2011 | 1525 | 0.060 |
Why?
|
| Animals | 18 | 2015 | 168561 | 0.060 |
Why?
|
| Body Size | 1 | 2007 | 461 | 0.060 |
Why?
|
| Nurses | 1 | 2013 | 2459 | 0.060 |
Why?
|
| Education, Medical | 1 | 2015 | 1717 | 0.060 |
Why?
|
| Conscious Sedation | 2 | 2011 | 528 | 0.060 |
Why?
|
| Astrocytoma | 1 | 2008 | 789 | 0.060 |
Why?
|
| Immunoconjugates | 1 | 2010 | 897 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2018 | 7716 | 0.060 |
Why?
|
| Back Pain | 1 | 2007 | 545 | 0.050 |
Why?
|
| Peptides | 1 | 2015 | 4392 | 0.050 |
Why?
|
| Leadership | 1 | 2012 | 1357 | 0.050 |
Why?
|
| Adipose Tissue, Brown | 1 | 2008 | 754 | 0.050 |
Why?
|
| Pattern Recognition, Automated | 1 | 2009 | 996 | 0.050 |
Why?
|
| Osteosarcoma | 1 | 2008 | 880 | 0.050 |
Why?
|
| Electrons | 1 | 2003 | 268 | 0.050 |
Why?
|
| Feasibility Studies | 3 | 2013 | 5062 | 0.050 |
Why?
|
| Colitis | 1 | 2010 | 1149 | 0.050 |
Why?
|
| Adipocytes | 1 | 2009 | 1182 | 0.050 |
Why?
|
| Graft Rejection | 1 | 2015 | 4393 | 0.050 |
Why?
|
| Radiation Effects | 1 | 1981 | 68 | 0.050 |
Why?
|
| Heart Transplantation | 1 | 2015 | 3119 | 0.050 |
Why?
|
| Fenoldopam | 1 | 2001 | 8 | 0.050 |
Why?
|
| Models, Biological | 2 | 2016 | 9581 | 0.050 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2002 | 177 | 0.050 |
Why?
|
| Low Back Pain | 1 | 2010 | 955 | 0.050 |
Why?
|
| Caregivers | 1 | 2013 | 2074 | 0.050 |
Why?
|
| Cerebrovascular Circulation | 2 | 2002 | 2732 | 0.050 |
Why?
|
| Education, Continuing | 1 | 2002 | 112 | 0.050 |
Why?
|
| Bone Marrow Cells | 1 | 2009 | 2513 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 2275 | 0.050 |
Why?
|
| Myocardium | 2 | 2012 | 4775 | 0.050 |
Why?
|
| Prevalence | 1 | 2017 | 15194 | 0.050 |
Why?
|
| Environmental Exposure | 2 | 2013 | 4231 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 9185 | 0.040 |
Why?
|
| Mice | 12 | 2015 | 81045 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2009 | 2066 | 0.040 |
Why?
|
| Artifacts | 2 | 2007 | 1903 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2010 | 3038 | 0.040 |
Why?
|
| Incidence | 1 | 2017 | 20928 | 0.040 |
Why?
|
| Benzamides | 1 | 2004 | 1378 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 5522 | 0.040 |
Why?
|
| Cadaver | 1 | 2003 | 1333 | 0.040 |
Why?
|
| Dopamine Agonists | 1 | 2001 | 355 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2015 | 4823 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2011 | 5978 | 0.040 |
Why?
|
| Dexmedetomidine | 1 | 2002 | 315 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 2015 | 2876 | 0.040 |
Why?
|
| Brain Ischemia | 1 | 2012 | 3258 | 0.040 |
Why?
|
| Deoxyglucose | 2 | 1995 | 337 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 5 | 2015 | 21821 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 39004 | 0.030 |
Why?
|
| Piperidines | 1 | 2004 | 1602 | 0.030 |
Why?
|
| Equipment Design | 1 | 2004 | 3582 | 0.030 |
Why?
|
| Amino Acids | 1 | 2022 | 1727 | 0.030 |
Why?
|
| Homeostasis | 2 | 2022 | 3335 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2007 | 2235 | 0.030 |
Why?
|
| Food | 1 | 2020 | 769 | 0.030 |
Why?
|
| Myocytes, Cardiac | 2 | 2015 | 1636 | 0.030 |
Why?
|
| Fluoroscopy | 2 | 2010 | 924 | 0.030 |
Why?
|
| Diffusion | 1 | 2017 | 832 | 0.030 |
Why?
|
| Fetus | 1 | 2022 | 1879 | 0.030 |
Why?
|
| Mass Screening | 1 | 2010 | 5238 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 396 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 6891 | 0.030 |
Why?
|
| Ammonia | 1 | 2015 | 239 | 0.030 |
Why?
|
| Hypnotics and Sedatives | 1 | 2002 | 1158 | 0.030 |
Why?
|
| Aging | 2 | 2011 | 8626 | 0.030 |
Why?
|
| Pattern Recognition, Visual | 1 | 2000 | 823 | 0.030 |
Why?
|
| Scattering, Radiation | 1 | 2015 | 498 | 0.030 |
Why?
|
| Mental Recall | 1 | 2000 | 1205 | 0.030 |
Why?
|
| Radioactive Tracers | 1 | 2013 | 73 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 9274 | 0.030 |
Why?
|
| Glycols | 1 | 2012 | 59 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 11472 | 0.030 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2015 | 257 | 0.030 |
Why?
|
| Sincalide | 1 | 1992 | 16 | 0.030 |
Why?
|
| Gallbladder Emptying | 1 | 1992 | 15 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 11039 | 0.030 |
Why?
|
| Melanoma | 1 | 2010 | 5462 | 0.030 |
Why?
|
| Esters | 1 | 2012 | 210 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2001 | 2043 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2013 | 8300 | 0.020 |
Why?
|
| Methods | 2 | 1989 | 1128 | 0.020 |
Why?
|
| Permeability | 1 | 2013 | 738 | 0.020 |
Why?
|
| Hemangioma, Cavernous | 1 | 1991 | 110 | 0.020 |
Why?
|
| Radioimmunodetection | 1 | 2010 | 46 | 0.020 |
Why?
|
| Population Surveillance | 1 | 1981 | 2616 | 0.020 |
Why?
|
| Cell Line, Tumor | 3 | 2013 | 16665 | 0.020 |
Why?
|
| Inflammation | 1 | 2010 | 10578 | 0.020 |
Why?
|
| Prognosis | 4 | 2013 | 29010 | 0.020 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2010 | 65 | 0.020 |
Why?
|
| Camptothecin | 1 | 2013 | 572 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1799 | 0.020 |
Why?
|
| Immobilization | 1 | 2011 | 236 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 10943 | 0.020 |
Why?
|
| Dextran Sulfate | 1 | 2010 | 236 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2003 | 8297 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2012 | 808 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 379 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2010 | 249 | 0.020 |
Why?
|
| Cardiac Output | 2 | 2002 | 853 | 0.020 |
Why?
|
| Documentation | 1 | 2015 | 865 | 0.020 |
Why?
|
| Stroke | 1 | 2012 | 9963 | 0.020 |
Why?
|
| Tail | 1 | 2009 | 97 | 0.020 |
Why?
|
| Epoxy Compounds | 1 | 2009 | 136 | 0.020 |
Why?
|
| Disease Models, Animal | 3 | 2015 | 18006 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2015 | 2372 | 0.020 |
Why?
|
| Fluorescence | 1 | 2011 | 751 | 0.020 |
Why?
|
| Hospitalization | 1 | 2008 | 10232 | 0.020 |
Why?
|
| Software | 3 | 2011 | 4434 | 0.020 |
Why?
|
| Education | 1 | 2011 | 543 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2011 | 5385 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 1996 | 1167 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 1831 | 0.020 |
Why?
|
| Drinking | 1 | 1989 | 197 | 0.020 |
Why?
|
| Sugar Acids | 1 | 1987 | 24 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2012 | 9735 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2015 | 3913 | 0.020 |
Why?
|
| Random Allocation | 1 | 2012 | 2425 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 15056 | 0.020 |
Why?
|
| Markov Chains | 1 | 2010 | 969 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 3133 | 0.020 |
Why?
|
| Hip | 1 | 1988 | 257 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2008 | 319 | 0.020 |
Why?
|
| Minerals | 1 | 1988 | 275 | 0.020 |
Why?
|
| Adipogenesis | 1 | 2009 | 358 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2010 | 1341 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2010 | 644 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 2085 | 0.020 |
Why?
|
| Thallium | 1 | 1985 | 101 | 0.020 |
Why?
|
| Gases | 1 | 1987 | 197 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2008 | 981 | 0.020 |
Why?
|
| Siblings | 1 | 2010 | 854 | 0.020 |
Why?
|
| Urologic Diseases | 1 | 2008 | 244 | 0.020 |
Why?
|
| Thorax | 1 | 2009 | 547 | 0.020 |
Why?
|
| Logistic Models | 2 | 2011 | 13403 | 0.020 |
Why?
|
| Biophysical Phenomena | 1 | 1987 | 327 | 0.020 |
Why?
|
| Integrases | 1 | 2008 | 533 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2001 | 8541 | 0.020 |
Why?
|
| Biophysics | 1 | 1987 | 383 | 0.020 |
Why?
|
| Anisotropy | 1 | 2009 | 1265 | 0.020 |
Why?
|
| Species Specificity | 1 | 2010 | 2479 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2010 | 1184 | 0.020 |
Why?
|
| Pentetic Acid | 3 | 1992 | 213 | 0.020 |
Why?
|
| Research Design | 1 | 2021 | 5979 | 0.020 |
Why?
|
| X-Rays | 1 | 1986 | 301 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2010 | 2003 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 8425 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 2885 | 0.020 |
Why?
|
| Gamma Rays | 1 | 1986 | 320 | 0.020 |
Why?
|
| Mathematics | 1 | 1986 | 727 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 2077 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 2011 | 1164 | 0.010 |
Why?
|
| Fever | 1 | 2011 | 1612 | 0.010 |
Why?
|
| Parathyroid Glands | 1 | 1985 | 509 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2010 | 3689 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2009 | 1353 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2000 | 5705 | 0.010 |
Why?
|
| Pressure | 1 | 1987 | 1203 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2007 | 780 | 0.010 |
Why?
|
| Tibia | 1 | 2009 | 1075 | 0.010 |
Why?
|
| Multifactorial Inheritance | 1 | 2010 | 1190 | 0.010 |
Why?
|
| Benzhydryl Compounds | 1 | 2009 | 840 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3862 | 0.010 |
Why?
|
| Disease Progression | 2 | 2011 | 13256 | 0.010 |
Why?
|
| Femur | 1 | 2009 | 1297 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4751 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 2633 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 4147 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2008 | 1905 | 0.010 |
Why?
|
| Curriculum | 1 | 2015 | 3589 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 2008 | 1171 | 0.010 |
Why?
|
| Osteogenesis | 1 | 2009 | 1299 | 0.010 |
Why?
|
| Thyroid Gland | 2 | 1986 | 1172 | 0.010 |
Why?
|
| Spine | 1 | 2009 | 1143 | 0.010 |
Why?
|
| Pregnancy | 2 | 2022 | 29087 | 0.010 |
Why?
|
| Eating | 1 | 1989 | 1535 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 2001 | 191 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2011 | 2041 | 0.010 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2001 | 64 | 0.010 |
Why?
|
| Government Agencies | 1 | 1981 | 156 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 1952 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2008 | 2713 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2009 | 2763 | 0.010 |
Why?
|
| Heart Rate | 2 | 2002 | 4091 | 0.010 |
Why?
|
| Mitochondria | 1 | 2013 | 3520 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2012 | 24913 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2008 | 2751 | 0.010 |
Why?
|
| Medical Record Linkage | 1 | 1981 | 284 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2015 | 4681 | 0.010 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2001 | 291 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2001 | 292 | 0.010 |
Why?
|
| Sodium Pertechnetate Tc 99m | 2 | 1991 | 57 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 3920 | 0.010 |
Why?
|
| Adiposity | 1 | 2009 | 1806 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 8621 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1994 | 1676 | 0.010 |
Why?
|
| Dominance, Cerebral | 1 | 2000 | 635 | 0.010 |
Why?
|
| Osteoporosis | 1 | 1988 | 1581 | 0.010 |
Why?
|
| Technetium Tc 99m Pentetate | 2 | 1988 | 68 | 0.010 |
Why?
|
| Middle Aged | 13 | 2002 | 213127 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2008 | 4839 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1992 | 3336 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2012 | 14554 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2009 | 3381 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 1981 | 1364 | 0.010 |
Why?
|
| Recurrence | 1 | 2008 | 8333 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2012 | 19223 | 0.010 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1995 | 87 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1991 | 4249 | 0.010 |
Why?
|
| Cobalt Radioisotopes | 1 | 1995 | 76 | 0.010 |
Why?
|
| Cell Line | 1 | 2009 | 15994 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 10472 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 1988 | 2861 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 9715 | 0.010 |
Why?
|
| Organometallic Compounds | 2 | 1988 | 665 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 11001 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1988 | 4246 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 1995 | 13019 | 0.010 |
Why?
|
| Indium Radioisotopes | 1 | 1992 | 118 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 7153 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 11690 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 2000 | 1669 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 9410 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 12958 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2007 | 3306 | 0.010 |
Why?
|
| Oxygen | 1 | 2002 | 4169 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 21719 | 0.010 |
Why?
|
| Gallbladder | 1 | 1992 | 301 | 0.010 |
Why?
|
| Aged | 7 | 2000 | 162944 | 0.010 |
Why?
|
| Renal Circulation | 1 | 1988 | 333 | 0.000 |
Why?
|
| Rotation | 1 | 1988 | 523 | 0.000 |
Why?
|
| Risk Factors | 2 | 2010 | 72145 | 0.000 |
Why?
|
| Obesity | 1 | 1988 | 12705 | 0.000 |
Why?
|
| Parathyroid Diseases | 1 | 1985 | 48 | 0.000 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1988 | 571 | 0.000 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1988 | 732 | 0.000 |
Why?
|
| Blood Glucose | 1 | 2000 | 6249 | 0.000 |
Why?
|
| Half-Life | 1 | 1986 | 658 | 0.000 |
Why?
|
| Brain Mapping | 1 | 2000 | 6669 | 0.000 |
Why?
|
| Air Pollution, Radioactive | 1 | 1982 | 10 | 0.000 |
Why?
|
| Soil Pollutants, Radioactive | 1 | 1982 | 2 | 0.000 |
Why?
|
| Plutonium | 1 | 1982 | 3 | 0.000 |
Why?
|
| Hyperplasia | 1 | 1985 | 1183 | 0.000 |
Why?
|
| Thyroid Diseases | 1 | 1985 | 378 | 0.000 |
Why?
|
| Alpha Particles | 1 | 1982 | 26 | 0.000 |
Why?
|
| Carcinoma, Papillary | 1 | 1987 | 781 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1991 | 2452 | 0.000 |
Why?
|
| Colorado | 1 | 1982 | 162 | 0.000 |
Why?
|
| Prostheses and Implants | 1 | 1988 | 1385 | 0.000 |
Why?
|
| Glomerular Filtration Rate | 1 | 1988 | 2167 | 0.000 |
Why?
|
| Cysts | 1 | 1985 | 676 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1995 | 4029 | 0.000 |
Why?
|
| Hip Fractures | 1 | 1988 | 954 | 0.000 |
Why?
|
| Models, Theoretical | 1 | 1991 | 3584 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1992 | 9144 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 1987 | 6347 | 0.000 |
Why?
|